Navigation Links
Pain in Biological Technology

Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading

... a significant improvement in patients' pain and ability to function normally. Tory McJunkin, MD, co-founder of Arizona pain Specialists, has a personal connection because ... "Clinical data show that this procedure relieves pain and improves patients' quality of life. I have ...

NeurogesX Reports Second Quarter 2009 Results

... Qutenza for treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain Entered exclusive agreement with Astellas ... focused on developing and commercializing novel pain management therapies, today reported results for ...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

... focused on developing and commercializing novel pain management therapies, today announced that the ... drug application (NDA) for Qutenza(TM) to manage pain associated with postherpetic neuralgia (PHN). ... focused on developing and commercializing novel pain management therapies. Its initial focus is on ...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

... product candidate for the treatment of acute pain and fever. The NDA was subsequently accepted for ... the unmet medical need for the treatment of pain and fever in patients who cannot take medication ... product candidate for the treatment of acute pain and fever. For more information about Cadence's ...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

... focused on developing and commercializing novel pain management therapies, today announced it will ... focused on developing and commercializing novel pain management therapies. Its initial focus is on ... Qutenza((TM)), a dermal patch designed to manage pain associated with peripheral ...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

... Selected Product Review pain PRODUCTS LIDODERM ((R)) : In September, ... education program on shingles and after-shingles pain in partnership with the National pain Foundation, The National Council on Aging, and ...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

... an efficacy standpoint, the exploratory daily pain scales for Dysmenorrhea and Non-Menstrual Pelvic pain demonstrated that women had minimal endometriosis pain symptoms at month six (mean scores of ...

Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board

... Julius' pioneering research in the biology of pain and welcome his participation on Solace's ... advisors to bring new ideas to the treatment of pain based on knowledge of its underlying mechanisms." ... targets that play a role in the pathogenesis of pain and that have disease-modifying potential in two ...

Anesiva Receives NASDAQ Delisting Staff Determination Letter

... of novel pharmaceutical products for pain management. The company's lead product candidate ... in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in ...

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy

... Patients with Moderate to Severe Post-Operative pain SYDNEY, Australia and BEDMINSTER, N.J., ... treatment of moderate to severe post-operative pain in patients following hip replacement surgery. ... to market complementary analgesic options for pain specialists, delivering greater patient ...

A Swiss Team Uses Transcranial MR-Guided Focused Ultrasound to Treat Patients With Functional Brain Disorders

... adult patients diagnosed with chronic neuropathic pain successfully underwent non-invasive deep brain ... transcranial MRgFUS and showed improvement in pain scores and reduction of pain medication with no adverse effects at three ...

King and Pain Therapeutics Announce REMOXY(R) NDA Update

... -- King Pharmaceuticals, Inc. (NYSE: KG ) and pain Therapeutics, Inc. (Nasdaq: PTIE ) today ... formulation for moderate-to-severe chronic pain designed to reduce potential risks of unintended ... was granted Priority Review. In December 2008, pain Therapeutics received a Complete Response Letter ...

NeurogesX Added to Russell 3000 Index

... focused on developing and commercializing novel pain management therapies. Its initial focus is on ... Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the ...

Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer

... ulcers in patients with mild-to-moderate pain in two Phase 3 studies. Dr. Sherman joins ... us manage the clinical development of our other pain therapies." In addition to his Horizon ... therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio ...

Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)

... for sale in the United Statesfor treatment of pain and fever NASHVILLE, Tenn., June 11 ... in the United States for the treatment of both pain and fever. Caldolor will be used primarily ... who are unable to receive oral therapies for pain relief and fever reduction. The only injectable ...

Lumbar Matrix(TM) Scan From SpineMatrix(R) Revolutionizes the Diagnosis of Low Back Pain

... Accurately Locates the Origin of pain While Reducing Healthcare Costs AKRON, Ohio ... technology that revolutionizes the way low back pain is diagnosed and treated, while also ... and the healthcare industry. Low back pain is the most common and costly disabling condition ...

NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)

... focused on developing and commercializing novel pain management therapies. Its initial focus is on ... Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the ...

New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives

... Three-of-Four Patients Surveyed Experience Daily pain From Rheumatoid Arthritis Despite Current ... revealed a majority of patients still suffer from pain (79 percent), fatigue (67 percent) and joint ... 24 percent of patients who self-inject experience pain upon injection and 20 percent experience ...

NeurogesX to Present at Needham Life Sciences Conference

... focused on developing and commercializing novel pain management therapies, announced today that ... focused on developing and commercializing novel pain management therapies. Its initial focus is on ... Qutenza(TM), a dermal patch designed to manage pain associated with peripheral ...

Phosphagenics Announces Completion of Transdermal Patch Prototypes

... out of the matrix. Oxycodone, a leading pain management drug, is currently administered either ... to become the first company to provide chronic pain sufferers with a sustained-release transdermal ... treatment that is capable of meeting the needs of pain sufferers and addresses the concerns of ...

NeurogesX Receives European Commission Approval for Qutenza(TM)

... Approved for peripheral neuropathic pain in non-diabetic adults SAN MATEO, Calif., ... focused on developing and commercializing novel pain management therapies, announced today that the ... for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in ...

Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108

... and other studies to build our pipeline of opioid pain management products." "We have already been ... licensing this novel approach of treating acute pain while reducing opioid-induced nausea and ... with partners motivated to introduce novel pain therapies that eliminate or significantly reduce ...

NeurogesX Reports First Quarter 2009 Results

... NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain Upcoming 2009 Milestones: - ... date of August 16, 2009 for Qutenza NDA to manage pain associated with PHN SAN MATEO, Calif., May 7 ...

Neurocrine Biosciences Reports First Quarter 2009 Results

... and in the femur was -0.28%. Analysis of the pain data, collected utilizing the Visual Analog Scale ... scales, daily assessment of non-menstrual pelvic pain was associated with a statistical "floor effect" ... with moderate or severe non-menstrual pelvic pain at baseline revealed statistically significant ...

Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc

... Currently the worldwide market for pain treatments is worth about US$26 billion and is ... 2011. In the US and Europe the moderate to severe pain market was estimated to be worth about $6.7 ... of indications including cardiovascular and pain indications. http://www.circpharma.com ...

NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results

... focused on developing and commercializing novel pain management therapies, today announced it will ... focused on developing and commercializing novel pain management therapies. Its initial focus is on ... Qutenza, a dermal patch designed to manage pain associated with peripheral ...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

... focused on developing and commercializing novel pain management therapies, announced today the ... (NDA) for Qutenza for the treatment of neuropatic pain associated with PHN to the U.S. Food and Drug ... recommending approval for peripheral neuropathic pain in non-diabetic adults either alone or in ...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

... FDA confirms durable pain palliation as an acceptable primary endpoint ... analysis of our Phase 3 trial featuring durable pain palliation as the primary endpoint adequately ... the second trial design evaluates reduction in pain as the primary endpoint. Having evaluated both of ...

Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers

... weak muscles and ultimately alleviating pain caused by strained tissue. While results vary, ... treated within the first 72 hours of injury, the pain can only worsen and extend treatment times and ... belief that as a result of their accident, their pain is life-long and permanent, but it's exactly the ...

Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge

... within 5 years. Patients suffering from wound pain have been difficult to assess and have been ... of every 10 chronic wound patients suffer from pain associated with their wounds, and if left untreated, this pain can lead to depression, loss of appetite, and ...

Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors

... LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and ... for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, ...

NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update

... focused on developing and commercializing novel pain management therapies, today announced it will ... for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in ... focused on developing and commercializing novel pain management therapies. Its initial focus is on ...

NeurogesX' Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

... Broad Label Indicated for Peripheral Neuropathic pain in Non-Diabetic Adults Conference Call ... focused on developing and commercializing novel pain management therapies, announced today that the ... for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in ...

Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA

... the treatment of post-operative inflammation and pain associated with ocular surgery. (Logo: ... In addition to potential vision loss, the severe pain and photophobia that accompany anterior uveitis ... approved for the treatment of inflammation and pain associated with ocular surgery. Difluprednate, ...

Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009

... LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and ... for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, ...

PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting

... to Validate a Capsaicin Model of Experimental pain in Healthy Human Volunteers," co-authored with ... Unit Head. Dr. Franke will address the use of pain modeling in early development and advantages of ... biomarkers to achieve the goal of alleviating pain and related symptoms. Dr. Franke will discuss how ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... Phase 3 registration trial evaluating durable pain palliation for OGX-011 in combination ... regarding the benefits of overall survival and pain palliation for the treatment of CRPC," said Cormack. "The endpoints of survival and pain palliation from our Phase 2 studies directly ...

Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain

... compared to placebo for the treatment of acute pain caused by mild-to-moderate ankle sprains, wrist ... patch can deliver effective relief of acute pain due to mild-to-moderate musculoskeletal injuries ... safe, effective and convenient site-specific pain management." ...

Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period

... LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and ... for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, ...

QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy

... and commercialisation of therapies for pain and central nervous system (CNS) disorders, ... Specifically, MoxDuo(TM) IR targets the acute pain market, a $2.5 billion segment of the $7 billion ... experiencing moderate to severe postoperative pain following total knee replacement will be treated ...
Other Contents
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... There were many fires burning in eastern New South ... July 11. , At 03:35 UTC on July 11 ... when Aqua passed over eastern New South Wales (NSW), ... natural-color visible image of the region and spotted smoke ... by MODIS,s thermal bands, are outlined in red. , ...
(Date:7/11/2014)... Canyon fire started near the City of Entiat on ... resources, the fire quickly grew to over 1,000 acres ... the fire is under investigation by the Washington Department ... with existing local resources in developing fire control strategies ... (USFS), Washington State Department of Natural Resources, (WA DNR), ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
(Date:7/11/2014)... from Scientology Churches and Missions are taking ... lectures, forums and conferences, information stands, sports events, and ... , Drug abuse is an international epidemic. According to ... alcohol and illicit drugs costs more than $425 billion ... healthcare. , In the face of statistics such ...
(Date:7/11/2014)... 11, 2014 Microbiology testing is a ... diagnostics industry, which is expected to pose the biggest ... sector owes its growth to the ongoing spread of ... worldwide and a major factor leading to the upsurge ... bio-terrorism, and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
(Date:7/11/2014)... The report, “Specialty Synthetic Fibers & Glass Fiber ... defines and segments the specialty synthetic fibers and ... of the volumes and values of types such ... UHMW Polyethylene, carbon fiber, partially oxidized polyacrylonitrile fiber, ... fiber, and liquid crystal polymer fiber and glass ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and segments ... revenue forecast. The well intervention services market in Europe is ... $3.4 billion by 2018, at a CAGR of 7% from ... Europe Well Intervention Market report, to get an idea of ... the segmentation in the Europe well intervention market, and is ...
Breaking Medicine News(10 mins):Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3
Other TagsOther Tags